Cover Image
Market Research Report
Product code 
685940

Geographic Atrophy - Pipeline Review, H2 2018

Published: | Global Markets Direct | 79 Pages | Delivery time: 1-2 business days

Price

Back to Top
Geographic Atrophy - Pipeline Review, H2 2018
Published: August 28, 2018
Global Markets Direct
Content info: 79 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Geographic Atrophy - Pipeline Review, H2 2018, provides an overview of the Geographic Atrophy (Ophthalmology) pipeline landscape.

Geographic atrophy is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retina which can lead to a loss of visual function over time. Symptoms include difficulty during reading. Risk factors include smoking, thyroid hormones or antacids and in patients with coronary heart diseases and cataract surgery. Treatment includes visual rehabilitation that can help with contrast sensibility and reading ability.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Geographic Atrophy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Geographic Atrophy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Geographic Atrophy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Geographic Atrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 3, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Geographic Atrophy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Geographic Atrophy (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Geographic Atrophy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Geographic Atrophy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Geographic Atrophy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Geographic Atrophy (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Geographic Atrophy (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Geographic Atrophy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10679IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Geographic Atrophy - Overview
    • Geographic Atrophy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Geographic Atrophy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Geographic Atrophy - Companies Involved in Therapeutics Development
    • Achillion Pharmaceuticals Inc
    • Acucela Inc
    • Alkeus Pharmaceuticals Inc
    • Allergan Plc
    • Apellis Pharmaceuticals Inc
    • Cell Cure Neurosciences Ltd
    • Colby Pharmaceutical Co
    • F. Hoffmann-La Roche Ltd
    • Foamix Pharmaceuticals Ltd
    • Genentech Inc
    • GenSight Biologics SA
    • Ionis Pharmaceuticals Inc
    • Johnson & Johnson
    • Novartis AG
    • NovelMed Therapeutics Inc
    • Ophthotech Corp
    • Ra Pharmaceuticals Inc
  • Geographic Atrophy - Drug Profiles
    • ACH-5548 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACU-6151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APL-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avacincaptad pegol sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brimonidine tartrate implant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLG-561 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPC-551 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EG-30 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FMX-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-030 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMR-59 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-FB-LRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPE-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NM-5072 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OpRegen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palucorcel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-6147 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-7171009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 to Inhibit Complement Factor D for Dry (atrophic) Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 to Inhibit Complement Factor D for Geographic Atrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 3 to Inhibit Complement Factor D for Geographic Atrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Factor D for Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tesidolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Geographic Atrophy - Dormant Projects
  • Geographic Atrophy - Discontinued Products
  • Geographic Atrophy - Product Development Milestones
    • Featured News & Press Releases
      • Jul 24, 2018: Apellis Pharmaceuticals APL-2 receives fast track designation from FDA for the treatment of patients with geographic atrophy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Geographic Atrophy, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Geographic Atrophy - Pipeline by Achillion Pharmaceuticals Inc, H2 2018
  • Geographic Atrophy - Pipeline by Acucela Inc, H2 2018
  • Geographic Atrophy - Pipeline by Alkeus Pharmaceuticals Inc, H2 2018
  • Geographic Atrophy - Pipeline by Allergan Plc, H2 2018
  • Geographic Atrophy - Pipeline by Apellis Pharmaceuticals Inc, H2 2018
  • Geographic Atrophy - Pipeline by Cell Cure Neurosciences Ltd, H2 2018
  • Geographic Atrophy - Pipeline by Colby Pharmaceutical Co, H2 2018
  • Geographic Atrophy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Geographic Atrophy - Pipeline by Foamix Pharmaceuticals Ltd, H2 2018
  • Geographic Atrophy - Pipeline by Genentech Inc, H2 2018
  • Geographic Atrophy - Pipeline by GenSight Biologics SA, H2 2018
  • Geographic Atrophy - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
  • Geographic Atrophy - Pipeline by Johnson & Johnson, H2 2018
  • Geographic Atrophy - Pipeline by Novartis AG, H2 2018
  • Geographic Atrophy - Pipeline by NovelMed Therapeutics Inc, H2 2018
  • Geographic Atrophy - Pipeline by Ophthotech Corp, H2 2018
  • Geographic Atrophy - Pipeline by Ra Pharmaceuticals Inc, H2 2018
  • Geographic Atrophy - Dormant Projects, H2 2018
  • Geographic Atrophy - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Geographic Atrophy, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018